Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis?

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 6, 2014, Pages

  Peyrin Biroulet, Laurent ^a,b   Bressenot, Aude ^a,b   Kampman, Wendy ^c  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Disease modification; Histologic assessment; Inflammatory bowel disease

Indexed keywords

BUDESONIDE; MESALAZINE; PREDNISOLONE SODIUM PHOSPHATE;

ARTICLE; CLINICAL ASSESSMENT; HEALING; HISTOLOGY; HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; COLITIS, ULCERATIVE; CYTOCHEMISTRY; DRUG MONITORING; INTESTINE MUCOSA; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

COLITIS, ULCERATIVE; DRUG MONITORING; HISTOCYTOCHEMISTRY; HUMANS; INTESTINAL MUCOSA; SEVERITY OF ILLNESS INDEX;

EID: 84901231807     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.022     Document Type: Article

References (43)

1. Peyrin-Biroulet L., Ferrante M., Magro F., et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. JCrohns Colitis 2011, 5:477-483.
2. Riley S.A., Mani V., Goodman M.J., et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32:174-178.
3. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9:483-489.e3.
4. Samuel S., Bruining D.H., Loftus E.V., et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013, 11:49-54.e1.
5. Turner D., Griffiths A.M., Veerman G., et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol 2013, 11:1460-1466.
6. Rosenberg L., Nanda K.S., Zenlea T., et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013, 11:991-996.
7. Korelitz B.I. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis 2010, 16:1628-1630.
8. Truelove S.C., Richards W.C. Biopsy studies in ulcerative colitis. Br Med J 1956, 1:1315-1318.
9. Dick A.P., Holt L.P., Dalton E.R. Persistence of mucosal abnormality in ulcerative colitis. Gut 1966, 7:355-360.
10. Florén C.H., Benoni C., Willén R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987, 22:459-462.
11. Gomes P., du Boulay C., Smith C.L., et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986, 27:92-95.
12. Geboes K., Riddell R., Öst A., et al. Areproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000, 47:404-409.
13. Lemmens B., Arijs I., Van Assche G., et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 2013, 19:1194-1201.
14. D'Haens G., Sandborn W.J., Feagan B.G., et al. Areview of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
15. Travis S.P.L., Higgins P.D.R., Orchard T., et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011, 34:113-124.
16. Marshall J.K., Thabane M., Steinhart A.H., et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, CD004115.
17. Kruis W., Kiudelis G., Rácz I., et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009, 58:233-240.
18. Hartmann F., Stein J. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2010, 32:368-376. BudeMesa-Study Group.
19. Chey W.Y. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001, 7(Suppl 1):S30-S33.
20. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, CD005112.
21. Gheorghe C., Cotruta B., Iacob R., et al. Endomicroscopy for assessing mucosal healing in patients with ulcerative colitis. JGastrointest Liver Dis 2011, 20:423-426.
22. Geboes K., Dalle I. Influence of treatment on morphological featuresof mucosal inflammation. Gut 2002, 50(Suppl 3):iii37-iii42.
23. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010, 16:338-346.
24. Isaacs K.L. How rapidly should remission be achieved?. Dig Dis 2010, 28:548-555.
25. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healingwith infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
26. Levine T.S., Tzardi M., Mitchell S., et al. Diagnostic difficulty arising from rectal recovery in ulcerative colitis. JClin Pathol 1996, 49:319-323.
27. Gramlich T., Petras R.E. Pathology of inflammatory bowel disease. Semin Pediatr Surg 2007, 16:154-163.
28. Cooney R.M., Warren B.F., Altman D.G., et al. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials 2007, 8:17.
29. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105.
30. Hanauer S., Schwartz J., Robinson M., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993, 88:1188-1197.
31. Hanauer S.B., Robinson M., Pruitt R., et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998, 115:525-532.
32. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
33. Azad S., Sood N., Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol 2011, 17:194-198.
34. Bessissow T., Lemmens B., Ferrante M., et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012, 107:1684-1692.
35. Melson J.E., Giusto D., Kwasny M., et al. Histopathology predictors of medically refractory ulcerative colitis. Dis Colon Rectum 2010, 53:1280-1286.
36. Hefti M.M., Chessin D.B., Harpaz N.H., et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 2009, 52:193-197.
37. Burger D.C., Thomas S.J., Walsh A.J., et al. Depth of remission may not predict outcome of UC over 2 years (abstr). JCrohns Colitis 2011, 5:S4.
38. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
39. Geboes K., Rutgeerts P., Olson A., et al. Infliximab results in reduction of inflammation and inflammatory markers in the mucosa of ulcerative colitis patients: the ACT 1 trial (abstr). Am J Gastroenterol 2005, 100:S287.
40. Löfberg R., Ostergaard Thomsen O., Langholz E., et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994, 8:623-629.
41. Paoluzi O.A., Pica R., Marcheggiano A., et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002, 16:1751-1759.
42. Sherlock M.E., Seow C.H., Steinhart A.H., et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, CD007698.
43. Filippi J., Allen P.B., Hebuterne X., et al. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets 2011, 12:1440-1447.